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A B S T R A C T
The aim of this article was to investigate the prevalence of hypertension with selected anthropometric variables in a
sample of hospitalized coronary heart disease (CHD) patients in Croatia. This study investigated patients hospitalized in
the period of October 1st 2007 until January 7th 2010 because of acute or chronic CHD in various hospitals in Croatia
(N=1,298). Prevalence of hypertension in surveyed patient population was high: 70.1% of participants had raised blood
pressure (BP) or previously diagnosed hypertension. Men had statistically significantly higher mean diastolic BP values
than women (78.91±8.97 vs. 77.12±10.61 mmHg, p=0.011). Prevalence of hypertension was statistically significantly
more frequent in women (80.6% vs. 65.8%, p<0.001). Hypertension still represents an important problem among hospi-
talized Croatian CHD patients. Its prevalence, unfortunately, continues to increase in this population, suggesting that
there is still great potential for improvement of preventive cardiology standards and measures that have already been un-
dertaken.
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Introduction
Hypertension is one of most thoroughly investigated
cardiovascular risk factors, which has been shown to
cause increased mortality from coronary heart disease
(CHD) and stroke1–4, therefore it can be considered as
one of the most preventable causes of premature death5
as it represents an independent risk factor for the devel-
opment of cardiovascular disease (CVD)6. It has been
demonstrated that this risk continually increases as the
values of blood pressure (BP) surpass that what is con-
sidered »normal limit« (for example persons aged 40–70
years have doubled risk of development of cardiovascular
disease for either increase of systolic BP of 20 mmHg or
diastolic BP of 10 mmHg4. Furthermore, it has been
shown that research of hypertension and other risk fac-
tors that are connected with it in different populations
represents one of basic preconditions for planning of ef-
fective prevention programmes based on evidence-based
medicine principles in order to prevent devastating ef-
fects of arterial hypertension7,8. INTERHEART study (A
global study of risk factors in acute myocardial infarc-
tion) showed that the presence of increased BP was re-
sponsible for 18% of population attributive risk for oc-
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currence of first myocardial infarction9. As numerous
studies have shown beneficial effects of reduction of BP
values, the importance of lifelong good BP control is con-
tinuously stressed, for it has also been observed that the
contribution of hypertension as a risk factor is addition-
ally potentiated in persons with other risk factors or tar-
get organ damage. Therefore it is clear why this approach
is also used in assessment of one’s total cardiovascular
risk. However, it should be noted that in persons who al-
ready have CVD or have high risk for development of
CVD, target BP values are somewhat lower than those
advised for the general population. This is due to the fact
that it has been reported that the risk for occurrence or
advancement of CVD is progressively increasing with BP
values higher than 110/75 mmHg10. Similar trend has
also been observed in persons that are known to have
CHD11. The answer to the question on what the BP tar-
get values in those patients should be like has been pro-
vided by large international clinical trials HOPE (Heart
Outcomes Prevention Evaluation), EUROPA (European
trial on reduction Of cardiac events with perindopril in
patients with stable coronary artery disease) and CAME-
LOT (Comparison of Amlodipine vs. Enalapril to Limit
Occurrences of Thrombosis) which have all shown that
BP reduction below previously recommended values pro-
vides further benefits in patients with high risk12–14.
According to the 2007 Guidelines from the European
Society of Cardiology (ESC) it is recommended for pa-
tients with CVD that, if possible, the BP values should be
<130/80 mmHg, while the values of <140/90 mmHg are
recommended for the primary prevention15,16.
Published data on Croatian general population report
quite heterogeneous prevalences of hypertension in Croa-
tia, which are ranging from 16.7% and 54%, depending
on which methodology was used and in which year the
survey was conducted17–20. Most recently published data
are those from the Croatian Adult Health Survey (CAHS)
which was conducted in 2003 in the general population,
reporting hypertension prevalence (mean systolic BP
values 140 mmHg or mean diastolic BP values 90
mmHg) in men of 40.5% and in women 34.9%21.
Materials and Methods
The survey included 1,298 patients hospitalized be-
tween October 1st 2007 and January 7th 2010 for acute or
chronic CHD in various hospitals in Croatia. It was per-
formed in the above mentioned period in Dubrava Uni-
versity Hospital (Zagreb), Sveti Duh University Hospital
(Zagreb), Bjelovar General Hospital, ^akovec General
Hospital, Karlovac General Hospital, Koprivnica General
Hospital, Slavonski Brod General Hospital, Vara`din Ge-
neral Hospital, Rijeka University Hospital Centre, Pula
General Hospital, Split University Hospital Centre, Du-
brovnik General Hospital and Zadar General Hospital.
A special questionnaire was produced for this study
which allowed recording of required data. Questionnaire
was made after series of consultations with experts and
literature and it was compiled by model of large clinical
trials conducted in Europe and Croatia [INTERHEART9,
EUROASPIRE (European action on secondary preven-
tion by intervention to reduce events) I22 and II23, EH-
-UH (Epidemiology of hypertension in Croatia)24, TAS-
PIC-CRO V (Treatment and secondary prevention of
ischemic coronary events in Croatia)25]. This allowed the
investigators to be able to efficiently compare results.
Most of the questions had multiple answers offered in ad-
vance to acquire greater accuracy. Data was collected on
patient history (personal and family history), age, sex
and information on cardiovascular risk factors and dis-
charge diagnoses. Physical examination was performed,
results of which were recorded – BP was measured twice
on both arms, after the patient had been sitting for at
least 10 minutes. Mean values of measured BP were used
for data analysis.
Patients were considered to have hypertension when
they fulfilled one of two criteria: either they had previ-
ously diagnosed hypertension (and were taking medica-
tions) or they had raised BP values at interview. The BP
values that were considered as raised at interview (and
therefore indicative of hypertension) were either 140
mmHg for systolic (130 mmHg in diabetics), or 90
mmHg for diastolic BP (80 mmHg in diabetics).
Data were collected by physicians or trained person-
nel (nurse), coded and entered into the electronic file.
Confidentiality of data was ensured in accordance with
current applicable codes, declarations and other provi-
sions. The results are shown in tables, and for quantita-
tive variables descriptive statistics were done with ap-
propriate measures of central tendency and variability
(mean, standard deviation, medians, associated inter-
quartile ranges). Normal distribution of quantitative va-
riables was tested by Kolmogorov-Smirnov test, and then
appropriate parametric (t-test for independent samples
and analysis of variance – ANOVA) or nonparametric
tests (Mann-Whitney U-test, Kruskal-Wallis test) were
used. The c2-test was also used.
Statistically significant results were considered those
with p values <0.05. Statistical analysis was made using
the software PASW version 17.02 (Chicago Inc., IL, www.
spss.com).
Results
A total of 898 subjects had hypertension (70.1%),
while 383 subjects (29.9%) had BP values within normal
range. Data on BP values was not available for 17 sub-
jects. Mean value of BP was 128.30±17.37 mmHg (sys-
tolic) and 78.39±9.50 mmHg (diastolic).
Men had statistically significantly higher mean dia-
stolic BP values than women (p=0.011, Table 1, Mann
Whitney U test).
Hypertension was statistically significantly more fre-
quent in women (p<0.001, Table 2, c2-test).
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Discussion
This article presents the available data on the preva-
lence of hypertension among Croatian hospitalized CHD
patients. Hypertension is one of interim cardiovascular
risk factors (much like overweight and obesity), and
therefore represents a more complex risk factor in com-
parison to behavioural factors that are completely de-
pendent on one’s behaviour, as there are many factors
that influence its onset and reduction26. Its role as one of
today’s most important preventable causes of premature
death is well recognized and it is an independent risk fac-
tor for development of CVD5. INTERHEART study sho-
wed that the presence of increased BP was responsible
for 18% of population attributive risk for occurrence of
first myocardial infarction9. As numerous studies have
shown beneficial effects of reduction of BP values, the
importance of lifelong optimal BP control is continuously
stressed as an important goal in order to reduce cardio-
vascular morbidity and mortality. The 2007 ESC Guide-
lines recommend for patients with CVD that, if possible,
the BP values should be <130/80 mmHg, while the val-
ues of <140/90 mmHg are recommended for the primary
prevention15,16. When analysing data from this study, in
order to allow comparisons with available data from two
other relevant studies which also examined this risk fac-
tor in Croatian patients with CHD (TASPIC-CRO V25
which was performed in years 2002 and 2003 and EURO-
ASPIRE III27 which was performed in 22 European coun-
tries in 2006, one of the countries that participated was
also Croatia), it was necessary to use the cut-off values
from older Guidelines, and therefore the BP values that
were considered as raised were either 140 mmHg for
systolic BP (130 mmHg in diabetics), or 90 mmHg for
diastolic BP (80 mmHg in diabetics).
According to those criteria, including also patients
with previously diagnosed hypertension, 898 subjects
(70.1%) had hypertension in this study. This represents
an increase in prevalence, as in TASPIC-CRO V the prev-
alence of this risk factor was 66%25 and in EUROASPIRE
III it was 56% for the whole sample in 22 European coun-
tries and 62% in the Croatian sample27. Our data shows
that there is an unfavourable trend of further increase of
already high prevalence of hypertension among Croatian
patients with CHD, which remains higher than Euro-
pean average. Bearing in mind the above mentioned dele-
terious effects of hypertension on cardiovascular morbidity
and mortality, one can only imagine that this will bring
further unfavourable trends on cardiovascular morbidity
and mortality in Croatia in coming years.
Literature shows that both systolic and diastolic BP
values represent an important risk factor for CHD
(which is especially true in older persons), but isolated
systolic hypertension is also an important risk factor for
the development of CHD and stroke28,29. The exact ef-
fect of hypertension can be difficult to measure, as it has
also been shown that when assessing cardiovascular
risk, one needs to take into account not just the current
values of BP, but also previous values, as well as degree
and duration of hypertension. In this study, men had
statistically significantly higher values of diastolic BP
when compared to women. Women had somewhat hi-
gher mean systolic BP values when compared to men;
however this difference did not achieve statistical sig-
nificance (Table 1).
Hypertension is statistically significantly more frequent
in women when compared to men (p<0.001, Table 2),
where as much as 80.6% of female CHD patients had this
risk factor, as compared to 65.8% of male CHD patients.
Although it has also been shown already in TASPIC-CRO
V that hypertension is more frequently present in female
CHD patients (76% in females vs. 62% in males), it is im-
portant to note that the prevalence of hypertension in
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TABLE 2
COMPARISON OF RAISED ARTERIAL BLOOD PRESSURE OR
HYPERTENSION ACCORDING TO SEX
Sex
Raised arterial blood pressure
or hypertension Total
No Yes
Men 311 (34.2%) 598 (65.8%) 909 (100.0%)
Women 72 (19.4%) 300 (80.6%) 372 (100.0%)
Total 383 (29.9%) 898 (70.1%) 1281 (100.0%)
c2=27.806; df=1; p<0.001
c2-test was used, p<0.05 is considered statistically significant
% – percent, df – degrees of freedom
TABLE 1
COMPARISON OF MEAN ARTERIAL BLOOD PRESSURES (SYSTOLIC AND DIASTOLIC) ACCORDING TO SEX
Measured value
(mmHg)
Sex N X SD Min.
Percentiles
Max. p
25. 50. (Median) 75.
Systolic
Men 909 127.89 16.56 87.50 116.25 127.50 138.75 182.50
0.245
Women 372 129.29 19.20 80.00 116.25 128.75 141.25 192.50
Diastolic
Men 909 78.91 8.97 51.00 72.50 80.00 83.75 121.25
0.011
Women 372 77.12 10.61 42.50 70.00 80.00 82.50 116.25
Mann-Whitney U-test was used, p<0.05 is considered statistically significant
mmHg – millimetres of mercury, N – number, SD – standard deviation, Min. – minimum, Max. – maximum, X – Mean
both sexes was lower25, and this represents a further
warning sign when it comes to assessment of prevention
and treatment of hypertension in Croatia.
These data show that hypertension still represents an
important problem among Croatian CHD patients. Its
prevalence, unfortunately, continues to increase in this
population, suggesting that there is still great potential
for improvement of preventive cardiology standards and
measures that have already been undertaken. There is a
need for more effective prioritized interventions target-
ing lifestyle changes and better control of hypertension
as an established cardiovascular risk factor, as it can be
expected that without this, the future of Croatian CHD
patients will be marked by increased cardiovascular mor-
bidity and mortality.
Acknowledgements
This study was supported by the Ministry of Science,
Education and Sports of the Republic of Croatia, project
number 108-1080135-126 (Risk factors by region in hos-
pitalised coronary heart disease patients, led by prof.
Mijo Bergovec) which is a part of a programme of projects
number 1080135 (Regionalism, dynamics of cardiovascu-
lar risk factors and health interventions, led by prof. Mijo
Bergovec).
R E F E R E N C E S
1. THE POOLING PROJECT RESEARCH GROUP, J Chronic Dis,
31 (1978) 201. — 2. NEATON JD, BLACKBURN H, JACOBS D, KUL-
LER L, LEE DJ, SHERWIN R, SHIH J, STAMLER J, WENTWORTH D,
Arch Intern Med, 152 (1992) 1490. — 3. MIURA K, DAVIGLUS ML, DY-
ER AR, LIU K, GARSIDE DB, STAMLER J, GREENLAND P, Arch In-
tern Med, 161 (2001) 1501. — 4. LEWINGTON S, CLARKE R, QIZIL-
BASH N, PETO R, COLLINS R, PROSPECTIVE STUDIES COLLABO-
RATION, Lancet, 360 (2002) 1903. — 5. GELEIJNSE JM, KOK FJ, GRO-
BBEE DE, Eur J Public Health, 14 (2004) 235. — 6. CHOBANIAN AV,
BAKRIS GL, BLACK HR, CUSHMAN WC, GREEN LA, IZZO JL JR,
JONES DW, MATERSON BJ, OPARIL S, WRIGHT JT JR, ROCCELLA
EJ, NATIONAL HEART, LUNG, AND BLOOD INSTITUTE JOINT NA-
TIONAL COMMITTEE ON PREVENTION, DETECTION, EVALUA-
TION, AND TREATMENT OF HIGH BLOOD PRESSURE, NATIONAL
HIGH BLOOD PRESSURE EDUCATION PROGRAM COORDINATING
COMMITTEE, JAMA, 289 (2003) 2560. — 7. WHITWORTH JA; WORLD
HEALTH ORGANIZATION, INTERNATIONAL SOCIETY OF HYPER-
TENSION WRITING GROUP, J Hypertens, 21 (2003) 1983. — 8. HE J,
MUNTNER P, CHEN J, ROCCELLA EJ, STREIFFER RH, WHELTON
PK, Arch InternMed, 162 (2002) 1051.— 9. YUSUF S, HAWKEN S, OUN-
PUU S, DANS T, AVEZUM A, LANAS F, MCQUEEN M, BUDAJ A, PAIS
P, VARIGOS J, LISHENG L, INTERHEART STUDY INVESTIGATORS,
Lancet, 364 (2004) 937. — 10. PASTOR-BARRIUSO R, BANEGAS JR,
DAMIAN J, APPEL LJ, GUALLAR E, Ann Intern Med, 139 (2003) 731.
— 11. SIPAHI I, TUZCU EM, SCHOENHAGEN P, WOLSKI KE, NICHO-
LLS SJ, BALOG C, CROWE TD, NISSEN SE, J Am Coll Cardiol, 48
(2006) 833. — 12. YUSUF S, SLEIGHT P, POGUE J, BOSCH J, DAVIES
R, DAGENAIS G, N Engl J Med, 342 (2000) 145. — 13. FOX KM, EURO-
PEAN TRIAL ON REDUCTION OF CARDIAC EVENTS WITH PERIN-
DOPRIL IN STABLE CORONARY ARTERY DISEASE INVESTIGA-
TORS, Lancet, 362 (2003) 782. — 14. NISSEN SE, TUZCU EM, LIBBY P,
THOMPSON PD, GHALI M, GARZA D, BERMAN L, SHI H, BUEBEN-
DORF E, TOPOL EJ, CAMELOT INVESTIGATORS, JAMA, 292 (2004)
2217. — 15. GRAHAM I, ATAR D, BORCH-JOHNSEN K, BOYSEN G,
BURELL G, CIFKOVA R, DALLONGEVILLE J, DE BACKER G, EBRA-
HIM S, GJELSVIK B, HERRMANN-LINGENC, HOES A, HUMPHRIES
S, KNAPTON M, PERK J, PRIORI SG, PYORALA K, REINER Z, RUI-
LOPE L, SANS-MENENDEZ S, SCHOLTE OP REIMERW, WEISSBERG
P, WOOD D, YARNELL J, ZAMORANO JL, WALMA E, FITZGERALD T,
COONEY MT, DUDINA A, EUROPEAN SOCIETY OF CARDIOLOGY
(ESC) COMMITTEE FOR PRACTICE GUIDELINES (CPG), Eur Heart
J, 28 (2007) 2375. — 16. GRAHAM I, ATAR D, BORCH-JOHNSEN K,
BOYSEN G, BURELL G, CIFKOVA R, DALLONGEVILLE J, DE BACKER
G, EBRAHIM S, GJELSVIK B, HERRMANN-LINGEN C, HOES A,
HUMPHRIES S, KNAPTON M, PERK J, PRIORI SG, PYORALA K,
REINER Z, RUILOPE L, SANS-MENENDEZ S, OP REIMER WS,
WEISSBERG P, WOOD D, YARNELL J, ZAMORANO JL, WALMA E,
FITZGERALD T, COONEY MT, DUDINA A, VAHANIAN A, CAMM J,
DE CATERINA R, DEAN V, DICKSTEIN K, FUNCK-BRENTANO C, FI-
LIPPATOS G, HELLEMANS I, KRISTENSEN SD, MCGREGOR K, SE-
CHTEM U, SILBER S, TENDERA M, WIDIMSKY P, ZAMORANO JL,
ALTINER A, BONORA E, DURRINGTONPN, FAGARD R, GIAMPAOLI
S, HEMINGWAY H, HAKANSSON J, KJELDSEN SE, LARSEN L, MAN-
CIA G, MANOLIS AJ, ORTH-GOMER K, PEDERSEN T, RAYNER M,
RYDEN L, SAMMUT M, SCHNEIDERMAN N, STALENHOEF AF, TOK-
GÖZOGLU L, WIKLUND O, ZAMPELAS A, EUROPEAN SOCIETY OF
CARDIOLOGY (ESC), EUROPEAN ASSOCIATION FOR CARDIOVAS-
CULAR PREVENTION AND REHABILITATION (EACPR), COUNCIL
ON CARDIOVASCULAR NURSING, EUROPEAN ASSOCIATION FOR
STUDY OF DIABETES (EASD), INTERNATIONAL DIABETES FED-
ERATION EUROPE (IDF-EUROPE), EUROPEAN STROKE INITIATI-
VE (EUSI), SOCIETY OF BEHAVIOURAL MEDICINE (ISBM), EURO-
PEAN SOCIETY OF HYPERTENSION (ESH), WONCA EUROPE (EU-
ROPEAN SOCIETY OF GENERAL PRACTICE/FAMILY MEDICINE),
EUROPEAN HEART NETWORK (EHN), EUROPEAN ATHEROSCLE-
ROSIS SOCIETY (EAS), Eur J Cardiovasc Prev Rehabil, 14 (2007) S1. —
17. TUREK S, RUDAN I, SMOLEJ-NARANCIC N, SZIROVICZA L, CUB-
RILO-TUREK M, ZERJAVIC-HRABAK V, RAK-KAIC A, VRHOVSKI-
-HEBRANG D, PREBEG Z, LJUBICIC M, JANICIJEVIC B, RUDAN P,
Coll Antropol, 25 (2001) 77. — 18. MIMICA M, CERIC B, KULCAR Z,
Lijec Vjesn, 103 (1981) 533. — 19. VULETIC S, BANTIC Z, DEZELIC D,
DEZELIC N, IVANKOVIC D, JAKSIC Z, JURESA V, KELNERIC D,
KERN J, KISIC M, Lijec Vjesn, 106 (1984) 443. — 20. JELAKOVIC B,
KUZMANIC D, RONCEVIC T, BORSO G, LAGANOVIC M, VDOVIC M,
Lijec Vjesn, 122 (2000) 192. — 21. ERCEG M, KERN J, BABIC-ERCEG
A, IVICEVIC-UHERNIK A, VULETIC S, Coll Antropol, 33 Suppl 1 (2009)
19. — 22. EUROASPIRE STUDY GROUP, Eur Heart J, 18 (1997) 1569.
— 23. EUROASPIRE II STUDY GROUP, Eur Heart J, 22 (2001) 554. —
24. JELAKOVIC B, ZELJKOVIC-VRKIC T, PECIN I, DIKA Z, JOVANO-
VIC A, PODOBNIK D, SMUC T, GAMBERGER D, KATIC K, KASNER
M, KUZMANIC D; EH-UH ISTRAZIVACKE SKUPINE, Acta Med Croa-
tica, 61 (2007) 287. — 25. REINER Z, MIHATOV S, MILICIC D, BER-
GOVEC M, PLANINC D, TASPIC-CRO STUDY GROUP INVESTIGA-
TORS, Eur J Cardiovasc Prev Rehabil, 13 (2006) 646. — 26. MULTI-
FACTORIAL TRIAL IN THE PREVENTION OF CORONARY HEART
DISEASE STUDY GROUP, Eur Heart J, 3 (1982) 184. — 27. KOTSEVA
K, WOOD D, DE BACKER G, DE BACQUER D, PYÖRÄLÄ K, KEIL U,
EUROASPIRE STUDY GROUP, Eur J Cardiovasc Prev Rehabil, 16
(2009) 121. — 28. FRANKLIN SS, LARSONMG, KHAN SA, WONG ND,
LEIP EP, KANNEL WB, LEVY D, Circulation, 103 (2001) 1245. — 29.
WILKING SV, BELANGER A, KANNEL WB, D’AGOSTINO RB, STEEL
K, JAMA, 260 (1988) 3451.
H. Vra`i}
University of Zagreb, Dubrava University Hospital, Division of Cardiology, Department of Internal Medicine,
Av. G. [u{ka 6, 10000 Zagreb, Croatia
e-mail: vrazic@gmail.com
H. Vra`i} et al.: Hypertension among Croatian CHD Patients, Coll. Antropol. 36 (2012) Suppl. 1: 217–221
220
PREVALENCIJA HIPERTENZIJE U HOSPITALIZIRANIH KORONARNIH BOLESNIKA U
HRVATSKOJ
Cilj ovog rada bio je istra`iti pojavnost hipertenzije uz odabrane antropometrijske varijable u uzorku bolesnika
hospitaliziranih zbog koronarne bolesti srca u Republici Hrvatskoj. U istra`ivanju su sudjelovali bolesnici hospitali-
zirani od 1. listopada 2007. g. do 7. sije~nja 2010. g. zbog akutne ili kroni~ne ishemijske bolesti srca u bolnicama diljem
Hrvatske (N=1.298). Prevalencija hipertenzije u istra`ivanoj populaciji bila je visoka: ~ak 70,1% ispitanika imalo je
povi{ene vrijednosti arterijskog tlaka ili od ranije postavljenu dijagnozu arterijske hipertenzije. Kod mu{kih ispitanika
srednje vrijednosti dijastoli~kog arterijskog tlaka bile su statisti~ki zna~ajno vi{e u odnosu na ispitanice (78,91±8,97
prema 77,12±10,61 mmHg, p=0,011). Prevalencija hipertenzije bila je statisti~ki zna~ajno ~e{}a kod `ena (80,6% prema
65,8%, p<0.001). Hipertenzija jo{ uvijek predstavlja zna~ajan problem u populaciji hospitaliziranih koronarnih bole-
snika u Hrvatskoj. Na`alost, u~estalost hipertenzije je u porastu u ovoj populaciji, {to pokazuje i dalje postoje velike
mogu}nosti pobolj{anja standarda preventivne kardiologije i u praksi ve} poduzetih mjera.
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